Opko Health Submits Claros 1 Prostate Cancer Test, Immunoassay System for FDA Approval

Nov 07, 2017

NEW YORK (360Dx) – Opko Health today announced the filing of a premarket approval application with the US Food and Drug Administration for a total prostate-specific antigen test with the firm's Claros 1 immunoassay analyzer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Featured White Papers

Advancing Patient Care and Aiding Diagnosis at the Point of Care

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Mar

20

Featured Webinar

A New Multiplex Syndromic System For Respiratory Diagnosis And Improved Patient Care

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Mar

21

Featured Webinar

A Long-Read vs. Short-Read Platform Comparison (Part 2): Best NGS Approaches for Human Transcriptome Sequencing

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Mar

28

Featured Webinar

The Human Gene Mutation Database: Empowering a Generation of Geneticists for Precision Medicine

The Human Gene Mutation Database (HGMD) is a manually curated, comprehensive collection of disease-causing, germline mutations. Since 1996, a team of experts has manually catalogued over a quarter of a million mutations for the database.

Apr

11

Featured Webinar

The 'Dark Matter' of Cancer Genomics: Revealing Undetected Structural Variants in Leukemia

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.

Menu